A Prospective Study of Clinical Outcomes and Recovery in Adults with Anti-LGI1 Autoimmune Encephalitis

What this Trial Is About

Researchers are studying anti-leucine-rich glioma-inactivated 1 LGI1 encephalitis, a type of autoimmune encephalitis that causes seizures, memory loss, behavior changes, sleep problems, and low sodium levels. This condition is the second most common autoimmune encephalitis after anti-NMDAR encephalitis. The study aims to prospectively investigate the clinical outcomes and factors associated with anti-LGI1 encephalitis, as previous prospective studies on this topic are limited. This observational study will enroll newly diagnosed patients during the acute stage before treatment. Participants will undergo various routine and advanced tests, including blood and cerebrospinal fluid analyses, brain MRI with multiple imaging techniques, EEG or continuous video EEG, PET scans, and neuropsychological assessments. These evaluations will be performed at the acute stage and throughout follow-up to analyze clinical outcomes and related factors. Participants will be monitored over time with assessments focused on seizure outcomes, clinical severity, recovery, and recurrence rates at one and two years. Secondary measures include memory tests and brain volume analysis. The study involves comprehensive testing and follow-up evaluations to better understand the disease progression and outcomes in patients with anti-LGI1 encephalitis.

A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis